ইউরোপীয় ইউনিয়ন - ডেনিশ - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotiske midler - xarelto, co-gives sammen med acetylsalicylsyre (asa) alene eller sammen med asa plus clopidogrel eller ticlopidin, der er indiceret til forebyggelse af atherothrombotic hændelser hos voksne patienter efter en akut koronar syndrom (acs) med forhøjet kardiale biomarkører. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. forebyggelse af venøs tromboembolisme (vte) hos voksne patienter, der gennemgår valgfri hofte- eller knæskifteoperation. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

ডেনমার্ক - ডেনিশ - SEGES Landbrug & Fødevarer

syngenta nordics a/s - fludioxonil - flydende bejdse - 480 g/l fludioxonil

ইউরোপীয় ইউনিয়ন - ডেনিশ - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiske midler - forebyggelse af venøs tromboembolisme (vte) hos voksne patienter, der gennemgår valgfri hofte- eller knæskifteoperation. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically ustabile pe patienter). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 og 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

ইউরোপীয় ইউনিয়ন - ডেনিশ - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiske midler - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

ডেনমার্ক - ডেনিশ - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - bupivacainhydrochlorid monohydrat - injektionsvæske, opløsning - 5 mg/ml

ডেনমার্ক - ডেনিশ - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm healthcare a/s - warfarinnatrium - tabletter - 2,5 mg

ডেনমার্ক - ডেনিশ - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - warfarinnatrium - tabletter - 2,5 mg

ইউরোপীয় ইউনিয়ন - ডেনিশ - EMA (European Medicines Agency)

intervet international b.v. - fluralaner, moxidectin - antiparasitic products, insecticides and repellents, endectocides, milbemycins - katte - til katte med eller i risiko for, blandet parasitangreb af flåter eller lopper og øremider, mave-nematoder eller hjerteorm. det veterinære lægemidler produkt er udelukkende angivet ved brug mod flåter eller lopper og en eller flere af de andre mål, parasitter, er angivet på den samme tid. til behandling af kryds og loppe-angreb i katte med øjeblikkelig og vedvarende flea (ctenocephalides felis) og skovflåten (ixodes ricinus) drab aktivitet i 12 uger. lopper og flåter skal vedhæfte til værten og påbegynde fodring for at blive udsat for det aktive stof. produktet kan bruges som en del af en behandlingsstrategi for loppe allergi dermatitis (fad). til behandling af angreb med øremider (otodectes cynotis). til behandling af infektioner med tarm rundorm (4. stadie larver, umodne og voksne af toxocara cati) og hageorm (4. stadie larver, umodne og voksne af ancylostoma tubaeforme). når det gives flere gange i en 12-ugers interval, produktet løbende forhindrer hjerteorm sygdom forårsaget af dirofilaria immitis.

ডেনমার্ক - ডেনিশ - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - warfarinnatrium - tabletter - 2,5 mg

ইউরোপীয় ইউনিয়ন - ডেনিশ - EMA (European Medicines Agency)

zoetis belgium s.a. - moxidectin, sarolaner, pyrantel embonat - antiparasitics - hunde - til hunde med, eller i fare, blandet eksterne og interne parasitangreb. det veterinære lægemidler produkt er udelukkende angivet ved brug mod flåter eller lopper og mave-nematoder er angivet på den samme tid. det veterinære lægemidler, også, giver samtidige effekt for forebyggelse af sygdom hjerteorm og angiostrongylosis. ectoparasitesfor behandling af kryds-angreb. det veterinære lægemiddel, har en umiddelbar og vedvarende kryds drab aktivitet for 5 uger mod ixodes hexagonus, ixodes ricinus og rhipicephalus sanguineus og til 4 uger mod dermacentor reticulatus;til behandling af loppe-angreb (ctenocephalides felis, og ctenocephalides canis). det veterinære lægemiddel, har en umiddelbar og vedvarende loppe drab aktivitet mod nye angreb i 5 uger;det veterinære lægemiddel, der kan bruges som en del af en behandlingsstrategi for kontrol af loppe allergi dermatitis (fad). mave-nematodesfor behandling af mave-rundorm og infektioner med hageorm:toxocara canis umodne voksne (l5) og voksne;ancylostoma caninum l4-larver, umodne voksne (l5) og voksne;toxascaris leonina voksne;uncinaria stenocephala voksne. andre nematodesfor forebyggelse af sygdom hjerteorm (dirofilaria immitis);for forebyggelse af angiostrongylosis ved at reducere graden af infektion med umodne voksne (l5) faser af angiostrongylus vasorum.